Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
2101-2120 of 2,251 trials

New T Cell Therapy for Pediatric Blood Cancers

We are testing a modified T cell treatment for children with relapsed or hard-to-treat B-cell leukemia and lymphoma. The study aims to evaluate safety and effectiveness in helping these patients achieve remission.

Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia and Lymphoma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesHematologyOncologyPediatrics

Advanced Solid Tumors: Testing IPN01195

We are studying a new medicine called IPN01195 to see how safe it is and what the best dose is for adults with advanced solid tumors. This trial aims to understand its effects on tumor activity and how it works in the body.

Advanced Solid Tumour3-6 monthsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementOncology

Staphylococcus Aureus Bacteremia: Comparing Antibiotic Durations

We are studying whether 7 days of antibiotic treatment is as effective as 14 days for patients with uncomplicated Staphylococcus aureus bacteremia. This may help reduce antibiotic use and hospital stays.

Staphylococcus aureus Bacteremia≤3 monthsMonitoring phase (IV)No PlaceboStandard MedicinesInfectious DiseasesInternal Medicine

AL Amyloidosis: Teclistamab Treatment Study

We are investigating whether teclistamab can improve blood health in patients with previously treated AL amyloidosis. This study will also look at the treatment's safety and its effects on quality of life.

Amyloid Light-Chain Amyloidosis>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Blood Cancers: IDP-121 Treatment Study

We are testing a new medication, IDP-121, for patients with relapsed or refractory blood cancers like multiple myeloma and B-cell lymphoma. The goal is to find the best dose and see how well it helps improve patient outcomes.

Chronic Lymphocytic Leukemia (CLL)B-cell LymphomasMultiple Myeloma (MM)6-12 monthsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesHematologyOncology

Neoadjuvant Chemo-Immunotherapy for Stage III PD-L1 Positive NSCLC

We are studying a combination of tislelizumab and chemotherapy for patients with stage III PD-L1 positive lung cancer. The aim is to see if this treatment improves surgery success and survival rates.

Stage III Non-Small Cell Lung CancerEfficacy phase (II)No PlaceboStandard MedicinesPartially RemoteOncologyPulmonology

Ravulizumab Dosing for PNH Patients

We are studying whether personalized dosing of ravulizumab is more effective than standard dosing for adults with PNH. This trial also looks at patient preferences and treatment costs.

Paroxysmal Nocturnal Hemoglobinuria1-2 yearsMonitoring phase (IV)Post-Trial Drug AccessNo PlaceboStandard MedicinesHematologyInternal Medicine

Emergency Pain Relief: Sublingual Sufentanil Study

We are investigating whether sublingual sufentanil can effectively manage moderate to severe pain in emergency patients after a single trauma. The study will also assess safety and compare it to standard pain management methods.

Pain in Limb6-12 monthsMonitoring phase (IV)No PlaceboInvestigational MedicinesInternal MedicineOrthopedics and TraumatologyOtolaryngologyPsychiatry

Atrial Fibrillation: Flecainide vs. Amiodarone

We are studying whether flecainide is more effective and safe than amiodarone for treating paroxysmal atrial fibrillation in patients with coronary disease. This trial aims to see if it can restore normal heart rhythm faster and reduce hospital visits.

Coronary Artery DiseaseParoxysmal Atrial Fibrillation>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCardiologyInternal Medicine

Glioblastoma Multiforme: Itraconazole with Radiotherapy and Temozolomide

We are studying whether adding Itraconazole to standard radiotherapy and temozolomide is safe for patients with newly diagnosed glioblastoma. Our goal is to find the best dose and understand its effects on survival and quality of life.

Glioblastoma≤3 monthsSafety phase (I)6-10 visitsNo PlaceboStandard MedicinesNeurologyOncology

Non-Small Cell Lung Cancer: Cemiplimab and TEDOPI® Study

We are testing a new combination therapy for patients with non-small cell lung cancer who have not progressed after initial treatment. The goal is to see if this therapy helps clear cancer markers and improves survival compared to standard treatment.

Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteOncology

Crohn's Disease in Children: Budesonide Treatment

We are studying a topical treatment with budesonide for children with Crohn's disease affecting the esophagus, stomach, or duodenum. The goal is to see if it helps reduce inflammation in these areas.

Crohn's Disease≤3 monthsConfirmation phase (III)No PlaceboStandard MedicinesGastroenterologyPediatrics

Remdesivir for COVID-19 in Kidney Transplant Patients

We are studying whether a 10-day treatment with remdesivir can help kidney transplant recipients with mild or no COVID-19 symptoms avoid severe illness. The trial will also look at the safety and health outcomes of these patients.

COVID-196-12 monthsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesInfectious DiseasesNephrology

Systemic Lupus Erythematosus: CC-97540 CAR T Cell Therapy

We are studying a new CAR T cell therapy for people with active lupus who haven't responded to standard treatments. The goal is to see if it can improve symptoms and overall health.

Systemic Lupus ErythematosusLupus Nephritis>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyRheumatology

Chronic HDV Infection: Tobevibart and Elebsiran Study

We are studying a new combination therapy for people with chronic HDV infection who haven't responded to prior treatment. The goal is to see if this therapy can effectively reduce the virus and improve liver health.

Chronic Hepatitis D Virus Infection>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementHepatologyInfectious Diseases

Psoriatic Arthritis: Lutikizumab and Risankizumab Study

We are testing the effectiveness and safety of a combination of two medications for adults with active psoriatic arthritis. This study aims to see if the combination works better than each medication alone.

Psoriatic Arthritis3-6 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesInternal MedicineRheumatology

Metastatic Colorectal Cancer: Cetuximab vs. Bevacizumab

We are studying whether continuing cetuximab treatment helps patients with specific types of metastatic colorectal cancer after their first treatment stops working. This trial compares it to another treatment option to see which is more effective.

Metastatic Colorectal CancerConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Low-Grade Upper Tract Urothelial Cancer: UGN-104 Treatment Study

We are studying a new treatment called UGN-104 for patients with low-grade upper tract urothelial cancer. The trial aims to see how well it reduces tumors and its safety compared to existing options.

Low-grade Upper Tract Urothelial Cancer1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncologyUrology

Oligometastatic Prostate Cancer: Lu-PSMA and Radiotherapy Study

We are investigating whether combining Lu-PSMA with stereotactic radiotherapy improves survival and quality of life for patients with oligometastatic prostate cancer compared to radiotherapy alone.

Metastatic Prostate Cancer3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesOncologyUrology

Sentinel Node Biopsy: ICG-99mTc-Nanoscan Tracer

We are studying a new hybrid tracer to improve the detection of sentinel nodes in cancer patients. This trial aims to see how well it works compared to traditional methods during preoperative imaging.

Melanoma and Other Head/Neck CancersEfficacy phase (II)No PlaceboStandard MedicinesOncologyOtolaryngology